| Name | Title | Contact Details |
|---|
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The companys initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for IBD, a mechanism already validated by a commercially available antibody. Enshos assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the companys pipeline.
Bury+Partners is a professional consulting firm serving the private sector as well as many public agencies. For 20 years, we've approached the challenges of our work with energy, expertise and a firm commitment to excellence. We expect to achieve nothing
KouLa IT Solutions is a Union City, CA-based company in the Business Services sector.
HEMTECH PERIPHERALS is a Staten Island, NY-based company in the Business Services sector.